Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia

Насонов, Е. Л.; Лила, А. М.; Мазуров, В. И.; Белов, Б. С.; Каратеев, А. Е.; Дубинина, Т. В.; Nikitinskaya, O.; Баранов, А. А.; Абдулганиева, Д. И.; Moiseev, Sergey; Zagrebneva, Alena I.

doi:10.47360/1995-4484-2021-239-254

Cited by 42 publications

(2 citation statements)

References 181 publications

(134 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Тактика применения РТМ и вакцинации при ИВРЗ в период пандемии COVID-19 представлена в недавно опубликованных рекомендациях Ассоциации ревматологов России [146], суть которых заключается в необходимости более строгой оценке показаний к проведению индукционной и поддерживающей терапии (см. табл.…”

Section: проблемы вакцинацииunclassified

B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19)

Nasonov

Авдеева²

2021

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

In patients with immune-mеdiated (autoimmune) rheumatic diseases (IMIRD), there are a number of factors (advanced age, uncontrolled inflammation, initially irreversible damage to internal organs, comorbid pathology, genetic and other factors) that can potentially lead to an increase in “sensitivity” to SARS-CoV -2 (severe acute respiratory syndrome coronavirus-2) and concomitant viral and bacterial infections, an increase in the risk of a severe course of COVID-19 (coronavirus disease 2019), a decrease in the effectiveness of therapy for both IMIRDs and COVID-19. An important area of pharmacotherapy for IMIRDs and other autoimmune diseases is associated with the use of anti-B-cell drugs, primarily rituximab (RTX), which is a chimeric (mouse/human) monoclonal antibody (mAb) to the CD20 antigen of B cells. At present, in Russia, the RTM biosimilar, acellbia (BIOCAD), is widely used, which is not inferior to RTX in terms of efficiency and safety. The problems of anti-B-cell therapy during the COVID-19 pandemic in relation to the risk of infection, severe course and insufficient effectiveness of vaccination against SARSCoV- 2 are considered. According to the recommendations of the Association of Rheumatologists of Russia, a more rigorous assessment of indications for induction and maintenance therapy of RTX therapy and harmonization of the timing of drug administration and vaccination is required.

show abstract

Section: проблемы вакцинацииunclassified

B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19)

Nasonov

Авдеева²

2021

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

show abstract

“…ЦШ представляет собой неконтролируемую системную воспалительную реакцию, развивающуюся под влиянием целого ряда факторов, включая инфекционные агенты и сопутствующие заболевания [2]. Вместе с тем остаются дискуссионными представления о ЦШ и синдроме высвобождения цитокинов [3]. Большинство исследователей считают, что непосредственное участие в формировании ЦШ у пациентов с COVID-19 принимают интерлейкин (ИЛ) 6, ИЛ-1β, фактор некроза опухоли-α (ФНО-α), интерферон-γ, макрофагальные воспалительные белки 1α и 1β и другие цитокины [4,5].…”

Section: Introductionunclassified

Characteristics of complex therapy of immuno-inflammatory rheumatic diseases in COVID-19 pandemic conditions

Samigullina¹,

Мазуров²,

Трофимов³

2021

Russian Medical Inquiry

View full text Add to dashboard Cite

The rapid spread of a new coronavirus infection (COVID-19) requires innovative solutions, including tactics optimization in using genetically engineered and targeted drugs in patients with immuno-inflammatory rheumatic diseases (RD). The authors studied the characteristics of the complex therapy of immuno-inflammatory RD in the COVID-19 pandemic conditions, analyzed the COVID-19 course in patients with RD who received combined therapy with genetically engineered and basic synthetic anti-rheumatic drugs and were under follow-up from March 2020 to March 2021. The researchers found that synthetic basic (methotrexate, leflunomide, etc.), targeted synthetic (tofacitinib, baricitinib, apremilast) and biologic disease-modifying antirheumatic drugs used in the RD treatment, except high-dose glucocorticoids and anti-B cell drugs (rituximab), do not have a negative effect and are not associated with a severe COVID-19 course. The use of interleukin-6 (IL-6) inhibitors is the standard pathogenetic therapy for cytokine release syndrome in COVID-19. Proactive therapy with IL-6 inhibitors provides inhibition of systemic inflammation and contributes to the suppression of cytokine storm syndrome, preventing the development of multiple organ failure and fatal outcome. KEYWORDS: rheumatic diseases, cytokine storm, multiple organ failure, genetically engineered biological drugs, interleukin-6, COVID-19. FOR CITATION: Samigullina R.R., Mazurov V.I., Trofimov E.A. Characteristics of complex therapy of immuno-inflammatory rheumatic diseases in COVID-19 pandemic conditions. Russian Medical Inquiry. 2021;5(5):260–267 (in Russ.). DOI: 10.32364/2587-6821-2021- 5-5-260-267.

show abstract

Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data)

Kulikov¹,

Muravyeva²,

Белов³

2022

Sovremennaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

Objective: to assess the safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (IRD) in real clinical practice.Patients and methods. A cross-sectional study of patients with IRD, who were admitted to V.A. Nasonova Research Institute of Rheumatology for inpatient or outpatient treatment. All patients received at least 1 dose of vaccine against COVID-19 (main group). The control group consisted of vaccinated persons without IRD. All participants were interviewed by the researcher by filling out a unified questionnaire, additional information was obtained from medical records.Results and discussion. The study included 204 patients with IRD (151 of them were vaccinated with Sputnik V, 31 with Sputnik Light, 19 with СoviVac, 3 with EpiVacCorona; 173 patients received the second component of vaccine) and 131 subjects without IRD (101 of them were vaccinated with Sputnik V, 17 – CoviVak, 5 – Sputnik Light, 2 – EpiVacCorona, 6 – Pfizer/BioNTech; 124 patients received the second component of the vaccine). The number of patients with IRD who had both local and systemic reactions after administration of the first component of the vaccine was significantly less than in the control group (19.6 and 38.9%, respectively; p<0.001). Similar differences were noted after the administration of the second component (15.6 and 27.4%, respectively; p=0.013). Adverse events (AEs) such as pain at the injection site without restriction of movement, weakness, fever, arthralgia/myalgia and chills were significantly more common in the control group after the administration of the first component of the vaccine. After complete immunization, AEs were absent in 35.8% of patients with IRD and in 21% of controls (p=0.006). Exacerbations of IRD and new autoimmune phenomena were not registered in any case.Conclusion. According to preliminary data, vaccination against COVID-19 in patients with IRD appears to be quite safe. Further studies are needed to investigate the safety, immunogenicity, and clinical efficacy of COVID-19 immunization in rheumatic patients.

show abstract

Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia

Cited by 42 publications

References 181 publications

B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19)

B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19)

Characteristics of complex therapy of immuno-inflammatory rheumatic diseases in COVID-19 pandemic conditions

Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data)

Contact Info

Product

Resources

About